Scalper1 News
Merger mania is heating up again as ethical drug firms rush to acquire each other and expand their portfolios. Salix Pharmaceuticals (SLXP) is the target of the latest potential bidding war. The stock surged 5% in heavy trade on Feb. 3 amid reports that Valeant Pharmaceuticals (VRX) was in talks to buy the gastrointestinal drug maker. It rose 4% Thursday as Valeant reportedly secured financing for a potential deal. Shares of Raleigh, N.C.-based Scalper1 News
Scalper1 News